Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03464461 · ClinicalTrials.gov registry record · Phase 4
Dosing of Ketorolac in the Emergency Department
A Phase 4 study, sponsored by University of Missouri-Columbia.
- Terminated
- Registry status
- Phase 4
- Development phase
- 289
- Enrollment target
NCT03464461: Clinical Trial Phase 4 study, sponsored by University of Missouri-Columbia.
NCT03464461 is a Phase 4 study that was terminated before completion, run by University of Missouri-Columbia. The registered enrollment target is 289 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03464461, a Phase 4 study, was terminated before completion, sponsored by University of Missouri-Columbia.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 289 participants
- Enrollment target
Study Summary
The optimal dose of ketorolac in the Emergency Department setting is no clear. We will compare 3 doses to determine the optimal dose.
Primary Outcome
The outcome measure is the average change in pain score. Change in pain score is calculated for each participant by subtracting the post-treatment pain score from the pretreatment pain score (i.e. pre-treatment pain score minus post-treatment pain score), then averaging them within each group. The pain score is collected using the visual analog scale, which is a 100mm line that participants make a mark on to indicate their pain intensity. The line is then measured from the left end of the line
Interventions
- DRUG Ketorolac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 4 |
Why NCT03464461 stopped before completion
NCT03464461 is an interventional study that assigns participants to a tested intervention. The registered 289 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 1 intervention - of which Ketorolac is the first listed.
NCT03464461 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03464461 about?
NCT03464461 is a clinical study titled "Dosing of Ketorolac in the Emergency Department". The optimal dose of ketorolac in the Emergency Department setting is no clear. We will compare 3 doses to determine the optimal dose.
What is the current status of trial NCT03464461?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 289 participants. The study started on 2018-05-01. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT03464461?
The interventions under investigation include: Ketorolac (DRUG).
Who is sponsoring clinical trial NCT03464461?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03464461's enrollment target sits among peer trials
289 298th of 2000 higher than 1,703 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06465199 · 289 participants · Phase 1
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI